Substance / Medication

Labetalol

Overview

Active Ingredient
labetalol
RxNorm CUI
6185

Indications

Labetalol hydrochloride tablets, USP are indicated in the management of hypertension. Labetalol hydrochloride tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.

Labeler: Bryant Ranch PrepackUpdated: 2026-02-09T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

[see Warnings ] Labetalol hydrochloride is contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity t

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

14 trials linked to this intervention

14
Total Trials
3
Recruiting
6
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Risk of postpartum readmission following discharge on nifedipine or labetalol for hypertensive disorders of pregnancy: A systematic review and meta-analysis.
Kanninen Tomi, Ortiz Vanessa, Alvarez-Perez Jesus et al. · Eur J Obstet Gynecol Reprod Biol · 2025
PMID: 40914007Meta-Analysis
Comparative efficacy and safety between intravenous labetalol and intravenous hydralazine for hypertensive disorders in pregnancy: A systematic review and meta-analysis of 19 randomized controlled trials.
Gonçalves Ocílio Ribeiro, Bendaham Lucas Cael Azevedo Ramos, Simoni Gabriel Henrique et al. · Eur J Obstet Gynecol Reprod Biol · 2024
PMID: 39522185Meta-Analysis
Oral nifedipine versus intravenous labetalol for hypertensive emergencies during pregnancy: a systematic review and meta-analysis.
Li Lin, Xie Wenxia, Xu Hao et al. · J Matern Fetal Neonatal Med · 2023
PMID: 37487762Meta-Analysis
Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.
van de Vusse Dylan, Mian Paola, Schoenmakers Sam et al. · Eur J Clin Pharmacol · 2022
PMID: 36104450Meta-AnalysisFull text (PMC)
Safety and efficacy of intravenous hydralazine and labetalol for the treatment of asymptomatic hypertension in hospitalised patients: A systematic review.
Cawoski Jocelyn R, DeBiasio Katie A, Donnachie Scott W et al. · Int J Clin Pract · 2021
PMID: 33400322Meta-Analysis
Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy.
Shi Qingquan, Leng Wenying, Yao Qiang et al. · Int J Cardiol · 2015
PMID: 25464243Meta-Analysis
Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.
Sanusi Ayodeji A, Leach Justin, Boggess Kim et al. · Obstet Gynecol · 2024
PMID: 38949541RCTFull text (PMC)
Optimal treatment for women with acute hypertension in pregnancy; a randomized trial comparing intravenous labetalol versus nicardipine.
Bij de Weg Jeske M, de Boer Marjon A, Gravesteijn Benjamin Y et al. · Pregnancy Hypertens · 2024
PMID: 39222572RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Labetalol (substance)
SNOMED CT
372750000
UMLS CUI
C0022860
RxNorm CUI
6185
Labeler
Bryant Ranch Prepack

Clinical Data

This intervention maps to 15 entities in the Healos knowledge graph.

4
Conditions
7
Biomarkers
3
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.